v3.26.1
FINANCIAL INSTRUMENTS
9 Months Ended
Mar. 31, 2026
Investments, All Other Investments [Abstract]  
FINANCIAL INSTRUMENTS

NOTE 10. FINANCIAL INSTRUMENTS

 

Cash and Cash Equivalents

 

The Company’s money market funds are categorized as Level 1 within the fair value hierarchy. As of March 31, 2026 and June 30, 2025, the Company’s cash and cash equivalents were as follows:

  

   As of March 31, 2026 
   Cost  

Unrealized

Gain (Loss)

   Fair Value  

Cash and

Cash Equivalents

 
Cash  $214,484   $      -    -   $214,484 
Level 1:                    
Money market funds   1,936,836    -   $1,936,836    1,936,836 
Total cash and cash equivalents  $2,151,320   $-   $1,936,836   $2,151,320 

 

   As of June 30, 2025 
   Cost  

Unrealized

Gain (Loss)

   Fair Value  

Cash and

Cash Equivalents

 
Cash  $130,288   $      -    -   $130,288 
Level 1:                    
Money market funds   6,702,437    -   $6,702,437    6,702,437 
Total cash and cash equivalents  $6,832,725   $-   $6,702,437   $6,832,725 

 

Contingent Consideration

 

Contingent consideration was valued at the time of acquisition using unobservable inputs and included using a Monte Carlo simulation model, which model incorporated revenue volatility, internal rate of return, and a risk-free rate. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management with the assistance, at times, of a third-party valuation specialist.

 

There is no contingent consideration as of March 31, 2026.

 

In July 2025 the Company finalized the contingent consideration related to the acquisition of BLI which resulted in a final contingent consideration cash payout of $1.50 million in October 2025.

 

The change in fair value of contingent consideration for BLI for the nine months ended March 31, 2026 was a non-cash expense of approximately $0.02 million included as change in fair value of acquisition contingent consideration in the condensed consolidated statement of operations. This reflects the change in the time value of money related to the present value of anticipated payment.

 

As of June 30, 2025, the Company’s contingent consideration liability balance was as follows:

 

  

Contingent Consideration at Purchase Date

  

Consideration Paid

  

Changes in Fair Value

   Fair Value  

Contingent Consideration

 
   As of June 30, 2025 
  

Contingent

Consideration

at Purchase

Date

  

Consideration

Paid

  

Changes in

Fair Value

   Fair Value  

Contingent

Consideration

 
Level 3:                         
Contingent consideration - BLI   7,324,900    (2,997,894)   (2,843,423)   1,483,583    1,483,583 
Contingent consideration - XRT   -    (499,288)   499,288    -    - 
Total contingent consideration  $7,324,900   $(2,997,894)  $(2,843,423)  $1,483,583   $1,483,583 

 

 

Actual BLI revenue through June 30, 2025 resulted in additional gross consideration of $1.50 million over the remainder of the contingent consideration payout period ending on July 31, 2025, payable in cash. Actual BLI revenue through July 31, 2025 did not trigger additional consideration. Accordingly, contingent consideration remaining for the BLI acquisition as of June 30, 2025 is calculated at the present value of the remaining $1.50 million cash discounted at risk-free interest rates from the estimated payment date.

 

The change in fair value of contingent consideration for BLI for the three and nine months ended March 31, 2025 was a non-cash expense of approximately $0.03 and $0.12 million, respectively, included as change in fair value of acquisition contingent consideration in the condensed consolidated statement of operations. This reflects the change in the time value of money related to the present value of anticipated payments.

 

The change in fair value of contingent consideration for XR Terra, LLC (“XRT”) for the nine months ended March 31, 2025 was a non-cash gain of approximately $0.03 million included as change in fair value of acquisition contingent consideration in the condensed consolidated statement of operations. This reflects the reversal of the estimated final consideration payment related to the acquisition of XRT. The contingent consideration payout period ended September 2024.